

3 September 2024

Pharmacy Data in Secondary Care – Cancer and Severe Asthma

I am conducting analysis on the treatment of cancer and severe asthma in secondary care and kindly request your help. I would be grateful if you could send me an extract of data from the hospital pharmacy database, showing quantities of medicines used. See specification below.

Data on usage of medicines from the hospital pharmacy system

Fields to include in the data extract from the hospital pharmacy database:

Field
Calendar year
Calendar month
Name of Health Board / Trust
Drug substance (INN name of drug)
Drug product pack name (substance name + strength + formulation)
Pack size
Quantity unit of measure (UOM)
Quantity issued

Time period: 1st Mar 2024 to 30th Jun 2024, or the latest available month

1. Drugs – Severe Asthma

- Benralizumab (Fasenra)
- Dupilumab (Dupixent)
- Mepolizumab (Nucala)
- Omalizumab (Xolair)
- Reslizumab (Cinqaero)
- Tezepelumab (Tezspire)

2. Drugs – Breast Cancer

- Abemaciclib (Verzenios)
- Palbociclib (Ibrance)
- Ribociclib (Kisqali)
- Apelisisib (Piqray)
- Fulvestrant (fulvestrant or Faslodex)

3. Drugs – Prostate Cancer

- Abiraterone (Zytiga + generics)
- Apalutamide (Erleada)
- Cabazitaxel (Jevtana + generics)
- Darolutamide (Nubeqa)
- Enzalutamide (Xtandi)

4. Drugs – Ovarian and Endometrial Cancers

- Niraparib (Zejula)
- Olaparib (Lynparza)

3 September 2024

- **Rucaparib (Rubraca)**
- **Dostarlimab (Jemperli)**

5. Drugs – Myeloproliferative Diseases

- **Momelotinib (Omjjara)**
- **Ruxolitinib (Jakavi)**
- **Fedratinib (Inrebic)**
- **Ropeginterferon alfa-2b (Besremi)**
- **Peginterferon alfa-2a (Pegasys)**
- **Epoetin alfa (Eprex, Binocrit)**
- **Epoetin beta (NeoRecormon, Mircera)**
- **Epoetin zeta (Retacrit)**

6. Drugs – Lung Cancer

- **Durvalumab**
- **Osimertinib**
- **Amivantamab**
- **Atezolizumab**
- **Nivolumab**

7. Drugs – Haematology

- **Acalabrutinib**
- **Ibrutinib**
- **Obinutuzumab**
- **Rituximab**
- **Venetoclax**
- **Zanubrutinib**

Unfortunately, the Pharmacy System, which was in place up until 6 June 2024 was a stock management system. The information requested above could not be extracted from this system.

Belfast Trust implemented [encompass](#) from 6 June 2024. Unfortunately, we are unable to access this information without completing a manual trawl, which would take significantly more than 18 hours to complete.

Belfast Trust considers that the cost of retrieving the information would be above the 'Appropriate Limit', as defined by the Freedom of Information Act under Section 12. Section 12 of the Freedom of Information Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit. The limit has been specified as £450 for public authorities such as Belfast Trust. This represents the cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

We are not required to comply with this request.